Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.

@article{Costantini1996CombinedOO,
  title={Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.},
  author={Vincenzo Costantini and Angelo Sidoni and R Deveglia and O A Cazzato and Guido Bellezza and Ivana Ferri and Emilio Bucciarelli and Giuseppe G. Nenci},
  journal={Cancer},
  year={1996},
  volume={77 6},
  pages={1079-88}
}
BACKGROUND A strong positive correlation exists between the breast cancer tissue content of either urokinase-plasminogen activator (uPA) or plasminogen activator, inhibitor type I (PAI-1), quantified in the tissue extracts by immunoassays, and the survival of patients with breast cancer. Furthermore, several studies assign to the urokinase-type plasminogen activator receptor (uPAR) a pivotal role in triggering the proteolytic activity of the urokinase pathway involved in tumor stroma… CONTINUE READING